<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096874</url>
  </required_header>
  <id_info>
    <org_study_id>RP 1310</org_study_id>
    <nct_id>NCT02096874</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema</brief_title>
  <official_title>The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Khaled Eye Specialist Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Khaled Eye Specialist Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as&#xD;
      Avastin on retinal ischemia in the setting of diabetic macular edema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major causes of vision loss in diabetic retinopathy are diabetic macular edema (DME)&#xD;
      characterized by thickening of the macula due to abnormal leakage of the retinal vasculature.&#xD;
      Ischaemic changes and microvascular pathologies have long been hypothesized to play a role in&#xD;
      the development of DME. In diabetic retinopathy, ischaemia stimulates the production of&#xD;
      vascular endothelial growth factor (VEGF), which can lead to the breakdown of blood-retinal&#xD;
      barriers, and may cause DME through an increase in retinal vessel permeability. DME is best&#xD;
      evaluated by optical coherence tomography (OCT) while retinal ischemia is determined by&#xD;
      Fluorescein angiography. With the avaiability of ultra wide field fluorescein angiography,&#xD;
      the investigators can now accurately measure the degree of ischemia in peripheral retina.&#xD;
      Thus, this study will provide us data on the degree of retinal ischemia in nonproliferative&#xD;
      diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) cases as well as the&#xD;
      measurable change that occurs in retinal ischemia after intra vitreal injection of&#xD;
      bevacizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral retinal ischemia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in peripheral retinal ischemia after intravitreal bevacizumab injection in non proliferative diabetic retinopathy and proliferative diabetic retinopathy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diabetic patients at age &gt;18year with DME&#xD;
&#xD;
          2. Scheduled for Avastin therapy&#xD;
&#xD;
          3. Adequate media to obtain OCT and UWFA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Macular pathology of any etiology&#xD;
&#xD;
          2. Preexisting systemic disease causing retinal ischemia&#xD;
&#xD;
          3. Previous laser or anti-VEGF treatment in past 3 months&#xD;
&#xD;
          4. Previous retina surgery in past 2 months&#xD;
&#xD;
          5. Allergy to fluorescein dye&#xD;
&#xD;
          6. Psychiatric disorder, Alzheimer disease and Dementia or any other disorder precluding&#xD;
             follow-up or continuation of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saba al Rashaed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Khaled Eye Specialist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ovais M Shaikh, MD</last_name>
    <phone>(966) 4821234</phone>
    <phone_ext>1139</phone_ext>
    <email>mshaikh@kkesh.med.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdul Rahman Hommadi</last_name>
    <phone>(966)4821234</phone>
    <phone_ext>3737</phone_ext>
    <email>ahommadi@kkesh.med.sa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Khaled Eye Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11462</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Khaled Eye Specialist Hospital</investigator_affiliation>
    <investigator_full_name>Saba al Rashaed</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Peripheral retinal ischemia</keyword>
  <keyword>ultra wide field fluorescein angiography</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

